|
WO2020099592A1
|
|
Synergistic combinations of methionine depletion agents and immune checkpoint modulators
|
|
WO2019042628A1
|
|
Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
|
|
EP3449935A1
|
|
Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
|
|
EP3187190A1
|
|
Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
|
|
FR3017299A1
|
|
PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES ENCAPSULATING A PLP ENZYME AND ITS COFACTOR
|
|
EP2813234A1
|
|
Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
|
|
FR3005420A1
|
|
METHOD OF STABILIZING SUSPENSIONS OF ERYTHROCYTES ENCAPSULATING AN ACTIVE INGREDIENT, SUSPENSIONS OBTAINED
|
|
KR20140145148A
|
|
Medicament for the treatment of acute myeloid leukemia (AML)
|
|
AU2010311515A1
|
|
Composition to induce specific immune tolerance
|
|
WO2010052315A1
|
|
Test for predicting neutralization of asparaginase activity
|
|
FR2944106A1
|
|
Method of determining inositol hexaphosphate (ihp).
|
|
CN105617366A
|
|
Medicament for the treatment of cancer of the pancreas
|
|
WO2009101467A1
|
|
Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
|
|
FR2928270A1
|
|
Formulation method for the prevention or treatment of bone metastases and other bone diseases
|
|
FR2919804A1
|
|
COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE
|
|
WO2007042647A1
|
|
Erythrocytes containing 5-fluorouracil (5-fu) and/or oxaliplatinum
|
|
AU2006238917A1
|
|
Erythrocytes containing arginine deiminase
|
|
CN101031339A
|
|
Lysis/resealing process and device for incorporating an active ingredient in erythrocytes
|
